Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Oncology · Lancet Oncol · 2026-11-01
Guideline
Guo et al. Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology OrganisationsOncology · Lancet Oncol · 2026-10-25
RCTn = 231
Tao et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trialOncology · J Clin Oncol · 2026-10-12
RCTn = 898
Poppe et al. Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)Oncology · Lancet Oncol · 2026-10-01
RCTn = 810
Sun et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trialOncology · J Clin Oncol · 2026-09-09
Secondary analysisn = 106
Subramanian et al. Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 TrialOncology · Lancet · 2026-09-06
RCTn = 417
Daly et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trialOncology · Lancet Oncol · 2026-09-01
Secondary analysisn = 505
Hennequin et al. High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trialOncology · Lancet Oncol · 2026-08-23
RCTn = 409
Bach et al. Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial